You are viewing the site in preview mode

Skip to main content

Advertisement

Uterotonic use immediately following birth: using a novel methodology to estimate population coverage in four countries

Article metrics

Abstract

Background

Postpartum hemorrhage (PPH) is the leading cause of maternal mortality in developing countries. While incidence of PPH can be dramatically reduced by uterotonic use immediately following birth (UUIFB) in both community and facility settings, national coverage estimates are rare. Most national health systems have no indicator to track this, and community-based measurements are even more scarce. To fill this information gap, a methodology for estimating national coverage for UUIFB was developed and piloted in four settings.

Methods

The rapid estimation methodology consisted of convening a group of national technical experts and using the Delphi method to come to consensus on key data elements that were applied to a simple algorithm, generating a non-precise national estimate of coverage of UUIFB. Data elements needed for the calculation were the distribution of births by location and estimates of UUIFB in each of those settings, adjusted to take account of stockout rates and potency of uterotonics. This exercise was conducted in 2013 in Mozambique, Tanzania, the state of Jharkhand in India, and Yemen.

Results

Available data showed that deliveries in public health facilities account for approximately half of births in Mozambique and Tanzania, 16% in Jharkhand and 24% of births in Yemen. Significant proportions of births occur in private facilities in Jharkhand and faith-based facilities in Tanzania. Estimated uterotonic use for facility births ranged from 70 to 100%. Uterotonics are not used routinely for PPH prevention at home births in any of the settings. National UUIFB coverage estimates of all births were 43% in Mozambique, 40% in Tanzania, 44% in Jharkhand, and 14% in Yemen.

Conclusion

This methodology for estimating coverage of UUIFB was found to be feasible and acceptable. While the exercise produces imprecise estimates whose validity cannot be assessed objectively in the absence of a gold standard estimate, stakeholders felt they were accurate enough to be actionable. The exercise highlighted information and practice gaps and promoted discussion on ways to improve UUIFB measurement and coverage, particularly of home births. Further follow up is needed to verify actions taken. The methodology produces useful data to help accelerate efforts to reduce maternal mortality.

Background

Globally, the number of maternal deaths has significantly declined, from an estimated 376,034 in 1990 to 292, 982 in 2013 [1]. The rates of change however are not sufficient to achieve a reduction in maternal mortality ratio by three-quarters by 2015 [1]. To accelerate the decline in countries where the largest numbers of deaths occur, the major causes of maternal mortality need to be addressed. Postpartum hemorrhage (PPH) is the leading cause in developing countries, and contributes nearly 20% of maternal deaths globally [2].

For the prevention of PPH, a uterotonic should be given to all women in the third stage of labor (i.e., immediately after birth), preferably oxytocin [3]. Prophylactic uterotonic use remains the most effective of the three components of active management of the third stage of labor (AMTSL). About 38% of women in developing countries who do not deliver with a skilled birth attendant [4] are not offered oxytocin or AMTSL. Misoprostol is an alternative uterotonic, and it has been used safely for PPH prevention at home births [5].

Numerous countries and development agencies have committed substantial resources to improving the coverage and quality of uterotonic use for PPH prevention, but lack a widely reported standardized indicator to monitor the use of prophylactic uterotonics. Current priority maternal health indicators [6] focus on contacts with the health system (e.g., percentage of births with a skilled attendant), but do not measure the content of care provided. The World Health Organization therefore recommends that a content-based indicator be used, defined as the percentage of women that receive a prophylactic uterotonic drug after birth among all women giving birth. Currently, data on prophylactic uterotonic use for all women giving birth are scarce. A 2012 survey conducted by the Maternal and Child Health Integrated Program found that only 15 of 37 USAID MNCH priority countries had an indicator for AMTSL and not all of these reported it to the national level [7]. None reported uterotonic coverage for women delivering at home.

To be able to measure this new content-based indicator for this key practice and track progress over time on prophylactic uterotonic use for all births, an exercise was developed to help national experts and stakeholders estimate national population-level coverage. For the purposes of this paper, this indicator is referred to “uterotonic use immediately after birth (UUIFB)” and is defined as 10 IU IM oxytocin or 600 mcg of misoprostol PO, given in the third stage of labor at any birth (i.e., at home or in a health facility). This article reports the UUIFB estimates derived from the exercise conducted in four settings: Mozambique, Tanzania, the state of Jharkhand, India, and Yemen.

Methods

Development of the methodology

A landscape analysis was conducted in mid-2012 to identify current and potential methods of estimating UUIFB nationally. Key findings were the scarcity of data on UUIFB and the need to improve estimation of this key intervention. Table 1 presents six possible methods for UUIFB estimation, roughly ranked for validity (i.e., accuracy). Generally, the methods that produce the most valid information are the more expensive and time-consuming to conduct. All methods are exclusively or mainly focused on facility-based deliveries and are unlikely to capture UUIFB at home births.

Table 1 Possible methods for estimating national UUIFB coverage

In December 2012 MCHIP presented the results of the landscape analysis to group of 19 experts and researchers working in international maternal health programs. The global expert panel confirmed the value of the process given that such estimates are not currently available. It reviewed possible methods of estimation (Table 1) and recommended as a rapid estimation exercise combining several methods to balance validity with feasibility considerations. First, the best available data from all available sources (i.e., the results of all methods encompassed by Methods 1–5 in Table 1) would be collected and evaluated for data quality by an in-country facilitator, preferably someone with a strong research background. Next, the Ministry of Health (MOH) would convene a panel of 15–20 experts with in-depth knowledge and experience with maternal health measurement and practice, such as senior MOH officials, researchers, representatives from technical organizations (e.g., WHO, UNICEF, donors, international and national non-governmental organizations) and leaders from professional associations. The panel would be surveyed (i.e., an example of Method 6 in Table 1) and then invited to a meeting to review the gathered information and use the algorithm described below to generate a national estimate of UUIFB coverage.

The algorithm used three data elements focusing on coverage in all birth locations, weighted by the percent of women giving birth in each of those locations. Information was gathered from publically available health management information systems (HMIS) or surveys or program data. When such data were not available, estimates were derived through panel deliberation and consensus based on the experience of the panel members themselves:

  1. 1.

    Distribution of birth locations

    • Proportion of facility-based births by sector: public, private, and non-governmental organization (NGO). Further stratification by health facility level if deemed relevant to the calculation by the panel (e.g. significantly different UUIFB coverage at hospitals compared to health centers).

    • Proportion of home births, disaggregated by attendance of a skilled provider

  2. 2.

    Measurements or estimates for the coverage of UUIFB using a recommended uterotonic (i.e., oxytocin, ergometrine or misoprostol) in each identified birth location.

  3. 3.

    Adjustments to those initial measurements or estimates of UUIFB, considering additional information on frequency of stockouts and uterotonic quality.

The group also considered supporting qualitative information derived from relevant documents, including national policies on uterotonic use, providers authorized to use uterotonics, presence of uterotonics on the List of Essential Medicines.

The quantitative information was utilized to construct a four-term equation applied to each relevant birth location and then summed over all those birth locations:

$$ \mathbf{UUIF}{\mathbf{B}}_{\mathrm{national}}=\Sigma \left({\mathrm{P}}_{\mathrm{a}}*\mathrm{E}\mathrm{s}{\mathrm{t}}_{\mathrm{a}}*\mathrm{S}{\mathrm{I}}_{\mathrm{a}}*{\mathrm{Q}}_{\mathrm{a}}\right)+\left({\mathrm{P}}_{\mathrm{b}}*\mathrm{E}\mathrm{s}{\mathrm{t}}_{\mathrm{b}}*\mathrm{S}{\mathrm{I}}_{\mathrm{b}}*{\mathrm{Q}}_{\mathrm{b}}\right)+\dots \left({\mathrm{P}}_{\mathrm{z}}*\mathrm{E}\mathrm{s}{\mathrm{t}}_{\mathrm{z}}*\mathrm{S}{\mathrm{I}}_{\mathrm{z}}*{\mathrm{Q}}_{\mathrm{z}}\right) $$

Where:

UUIFBnational is the national estimate of UUIFB coverage

Pa is the proportion of births in Location A (e.g., home, public facility, etc.)

Esta is the initial estimate of UUIFB coverage in Location A

SIa is the “stock-in” rate of uterotonic in Location A (i.e., commodity availability or 100% minus the stock-out rate)

Qa , an optional factor, is the estimated quality (i.e., biological potency) of the uterotonic in Location A

Σ indicates that this calculation is performed for all identified birth locations (i.e., Locations A to Z).

Country selection

Four settings were purposively selected. The settings, which cover a variety of geography and contexts, had MOH interest and were programmatically important because of large numbers of maternal deaths. Maternal mortality ratio estimates in the four settings are high (i.e., 270–480 per 100,000 live births) [8]. A single Indian state was selected because of the heterogeneity of health service delivery across India and the fact that authority is decentralized to states for health programs.

Implementation of the estimation exercise

General description and preparation

The exercises were conducted in Mozambique, Tanzania and Jharkhand, India between April and July 2013 and in Yemen December 2013. The approach was the Modified Delphi method [9-11] led by a small group of in-country facilitators to help the expert group reach a consensus on the national coverage estimate. First, before convening the expert group, background information was collected and reviewed on location of births, policies and guidelines related to uterotonic use, the national List of Essential Medicines, peer-reviewed literature and program reports on availability of uterotonics, and any other information relevant to UUIFB coverage estimates. Supplemental information on providers sanctioned to provide uterotonics following birth, types of uterotonics in use, and the existence and coverage of community-based misoprostol distribution for home births also were gathered. HMIS reports, Demographic and Health Surveys (DHS), and/or Multiple Indicator Cluster Survey (MICS) reports, peer-reviewed literature, health facility assessments and other relevant documents were collected and reviewed.

A national expert panel of 15 to 30 professionals was called to a one-day meeting. The panel composition varied between countries, but was always comprised a diverse set of experts that included MOH officials working on maternal and newborn health services, senior members of national professional associations, representatives from private sector associations, key maternal health academics and researchers, experts in commodity supplies, facility-based service providers, and stakeholders familiar with prevailing practices during home birth (see Table 2). Before the exercise, participants were sent a brief survey to gather key information on delivery locations, national policies, guidelines and practices. The consultation with the expert panel was a facilitated three step process, described below.

Table 2 Number and description of experts participating in each country panel

Step 1

The expert panel first reviewed available evidence on the location of births in the country from the most recent DHS. Because no DHS had been conducted in Jharkhand or Yemen, a similar population-based survey was used for these estimates [12,13]. The group then reviewed HMIS data for further stratification by level of service delivery (i.e., births at regional hospitals or lower level health facilities) if it was deemed relevant to UUIFB provision.

Step 2

Beginning with data sources considered most valid and representative (as described in Table 1), the panel then discussed initial estimates of UUIFB in each birth location identified in Step 1. The panel considered all available data, which had been gathered by the facilitator in consultation with panel members. The data sources ranged from observational studies of quality (Mozambique and Tanzania for public facilities), to HMIS data (all but Yemen), to opinion of the panel members when no other data source was available, as was usually the case for non-public sector facilities. Variations on measurements around timing of the provision of uterotonic reported in the available data sources (e.g., within one versus three minutes after birth) were discussed, and a consensus decision was made about which measurements would be used on a country-by-country basis.

Step 3

Finally, the panel considered factors that might require adjustment of the initial estimates of UUIFB in each birth location, such as stock-out rates and reports on drug quality or potency. The modifying factors were used to adjust the initial estimate. The qualitative information (i.e., on providers authorized to use uterotonics, policies, and presence of the uterotonics on the List of Essential Medicines) was used as a check on the likely accuracy of quantitative estimates.

Final calculation and recommendations

Table 3 summarizes all the data sources used for the calculation. The calculation of the UUIFB value was done by the expert panel, facilitated by use of a spreadsheet that calculated the weighted average. Upper and lower bounds on the estimate then were assigned based on a consensus view of the uncertainty of various data elements included in the calculation. Panel members discussed key gaps in information, likely causes of lower than expected coverage and recommendations for improving UUIFB coverage and its estimation.

Table 3 Data sources used for parameters needed to estimate UUIFB coverage

MCHIP also reconvened the global expert panel in July 2013 to review the methodology in light of results from the initial three exercises.

Ethical review

No IRB approval was required because it was not human subjects research, gathered no primary data, and used only publically available data.

Results

Estimates of distribution of births by location

Figure 1 presents the distribution of births by delivery location in the four settings, generated by the expert panels [14,15]. In Tanzania and Mozambique, home births account for close to half of all deliveries (48.1 and 45.2%, respectively), while in Jharkhand they account for 62.0%, and 76.0% in Yemen. Facility-based deliveries in public hospitals and health centers account for 54.6% of births in Mozambique, 41.0% in Tanzania, and 16.0% in Jharkhand. In the case of Mozambique, facility deliveries outside the public sector were negligible (0.2%), but in other settings, a substantial fraction of births occur outside the public sector, as in Jharkhand (20.8% in private; 0.8% in faith-based NGO) and Tanzania (7.5% in faith-based NGO facilities). Data from public and private facilities are combined in Yemen.

Figure 1
figure1

Estimates of distribution of births by location in each setting. Dark red represents Home births without a skilled birth attendant (SBA); pink represents Home births with a skilled birth attendant; green represents births in public hospitals and health facilities; purple represents births in private health facilities; blue represents other health facilities; orange represents missing data.

Because of known differences in coverage of UUIFB in different levels of public health facilities in some settings and for births attended by skilled birth attendants (versus non-skilled attendants), some refinements were applied to the estimates of distribution of birth locations and these are shown in Figure 1. In Tanzania, public facility births were further stratified by level (health center versus hospital). A small fraction of home births are attended by a skilled birth attendant (SBA) in three of the settings (Tanzania, Yemen and Jharkhand); and a small percentage (0.2%) of facility-based deliveries in public facilities are conducted by non-qualified personnel in Jharkhand.

Initial UUIFB coverage estimates by delivery location

All available information was reviewed and discussed to arrive at UUIFB coverage for each identified delivery location. Data from facility-based assessments were used where available, complemented by HMIS data. In Yemen, no specific data on UUIFB in any location were available, so the expert panel made estimates, based on its consensus opinion.

For facility-based birth locations, initial UUIFB coverage estimates ranged from a low of 70% in public facilities in Yemen to as high as 100% for private facility births in Jharkhand and Mozambique. In Mozambique and Tanzania, recent observational assessments of the quality of labor and delivery care had been conducted, from which the panel was able to draw facility-based UUIFB provision [16,17]. Based on these data the Tanzanian panel estimated UUIFB coverage in most public and private facilities to be 81.5%, averaging findings from health centers (71%) and central hospitals (99%). The Mozambique panel took the national HMIS reported uterotonic use (94%), and revised this figure downward based observational assessment finding that uterotonic use within three minutes of birth (i.e., an even more stringent standard than UUIFB implies) was 68%. In Yemen, UUIFB coverage was estimated to be 70% for facility deliveries. In Jharkhand UUIFB coverage was estimated to be 90% for all public and private facilities.

For home births, little information on UUIFB coverage was available. In Jharkhand approximately 15% of deliveries occur at home with an SBA, and the panel’s consensus opinion was that UUIFB coverage in this setting was approximately 85%. Taking into account the distribution of births and UUIFB in this delivery location, UUIFB coverage for home births attended by an SBA contributed 29.8% of total UUIFB coverage in Jharkhand and 42.9% in Yemen, but in Tanzania it contributed only 2.0% and in Mozambique 0%. In all settings, home-based deliveries without an SBA were estimated as having 0% UUIFB coverage. This reflected the absence of home-based uterotonic provision programs, such as distribution of misoprostol for non-SBA attended home births.

Adjustments to initial coverage estimates by birth location

Stockouts of uterotonic were a key modifier applied to the original coverage estimate.

Estimated stockouts of uterotonic for Jharkhand ranged from 0-33%, with the opinion of the panel that stockouts were more frequent at more peripheral facilities. Stockouts at all facilities in Tanzania were estimated at 2%, taking facility audit findings into consideration. In Mozambique, a 2011 national UNFPA commodity availability assessment showed a nationwide stockout rate of 2.5% across all types and levels of facilities, both public and private [18]. The expert panel in Yemen calculated a uterotonic access rate, which factored in stockouts as well as other supply/access issues, for SBAs at home births at 90% and 50% for facility births. This is shown in Table 4.

Table 4 Calculation of UUIFB coverage estimates for Mozambique, Tanzania, Jharkhand (India), and Yemen

The Jharkhand expert panel incorporated an assumption that 40% of oxytocin samples were not potent because of poor storage, based on findings from a recent assessment at health facilities and took this into account in their estimation of the effective coverage rate of quality uterotonic. This adjustment was not done in the other three settings. The final estimates of coverage of UUIFB among all births were 15% in Yemen, 40% in Tanzania, 43% in Mozambique, and 44% (unadjusted) or 32% (quality adjusted) in Jharkhand. Figure 2 presents the contributions from each setting to the national coverage estimate and Table 4 summarizes the data elements used for calculation of UUIFB in the four settings. Table 5 presents the key recommendations and actionable outcomes from each exercise.

Figure 2
figure2

Final consensus estimate of total UUIFB coverage. Dark red represents Home births without a skilled birth attendant (SBA); pink represents home births with a skilled birth attendant; green represents births in public hospitals and health facilities; purple represents births in private health facilities; blue represents other health facilities; orange represents missing data.

Table 5 Recommendations by the expert panel from the UUIFB estimation exercise in each setting

Discussion

This new methodology was effective in generating a national-level estimate of UUIFB coverage in all four settings and therefore filled the need for a content-based PPH-related indicator within national safe motherhood programs. Although there currently is no way to validate the findings, the exercise produced results that were acceptable to the expert panel. It provided the MOH with measurement for monitoring and planning, as well as actionable information to address gaps in data collection, data quality and service provision.

PPH remains the leading cause of maternal death in most developing countries. AMTSL substantially reduces the incidence of severe PPH [19], and more recent evidence concludes that use of a uterotonic is the most effective component of AMTSL [20,21]. AMTSL has been widely promoted in skilled attendance at birth particularly at health facilities. At the same time, at least 19 countries have introduced or expanded distribution of misoprostol as a PPH prevention strategy at home births [22]. National safe motherhood programs, however, do not have data on national UUIFB coverage for all births to inform planning and evaluation because data on this intervention are not easily measured on a population basis. Health facility readiness assessments done on a nationally representative sample of facilities (e.g., Service Provision Assessments, Service Availability and Readiness Assessments, and the Averting Maternal Death and Disability assessments) are conducted occasionally and typically measure inputs (such as the availability of uterotonics) and not actual practice. Facility assessments using observation of labor and delivery practices produce the most valid data, but are even less commonly done, especially on a nationally representative sample of facilities. One such observational assessment, conducted mainly in district and referral hospitals in seven countries in Asia, Africa and Latin America from 2005–2006, found that almost all (98–100%) women received a uterotonic during the third or fourth stage of labor [23]. Few national HMIS currently record and report data on AMTSL or UUIFB. Data from all three of these sources often are limited to public sector facilities and do not take account of the substantial proportion of women who give birth at home. Population-based surveys such as DHS and MICS rely on self-reported data and therefore do not produce reliable information on the coverage of UUIFB, as a recent study has shown that women’s recall about the receipt of an injection immediately following birth is very poor [24].

The uterotonic estimation exercise described in this paper was devised to fill this information gap on UUIFB coverage. The method is similar to that used for the Maternal and Neonatal Program Effort Index to estimate national programmatic effort in the reduction of maternal and newborn death [25] and the method has also been used to estimate the effectiveness of maternal and newborn interventions on mortality [10,11]. Participants in several settings stated that they felt the process was feasible and transparent and helped them arrive at an estimate accurate enough to be actionable. For example, the panels identified access to uterotonics as the largest contributor to suboptimal national UUIFB coverage. Because the methodology estimates population coverage, it should allow Ministries of Health to be more strategic in identifying the most potentially effective strategies to improve UUIFB coverage for all births regardless of delivery location, and thereby promote more equitable uterotonic coverage.

The exercise highlighted how uterotonic availability and quality can influence national UUIFB coverage. Yet uterotonic availability at the facility level is not tracked nationally in any of the four settings. In Tanzania, the national program tracks oxytocin, ergometrine and misoprostol stockouts separately, but does not identify when facilities experience a stockout of all uterotonics simultaneously. Degradation of injectable uterotonics due to exposure to light and heat has been documented [26], and recent studies of uterotonics collected from health facilities and pharmacies in developing countries have raised concerns about quality, particularly of oxytocin [27-29]. A study in India found 22%-50% of oxytocin and 44-54% of methylergometrine samples did not meet manufacturer specifications for potency (90%-110% active pharmaceutical ingredient) in Uttar Pradesh, a neighboring state to Jharkhand. [Personal Communication, Nitya Nand Deepak, PATH/India] Concerns persist as well about misoprostol deterioration due to moisture, if not packaged properly [30]. Clearly, efforts to raise effective coverage can be blunted by inattention to pharmaceutical quality. This should be taken into account as national governments formulate strategies to raise UUIFB coverage rates.

This exercise also highlighted the programmatic gaps around UUIFB for home births. Although WHO recommends misoprostol for PPH prevention at home births where SBAs and oxytocin are not available [4], none of the four settings studied in this exercise currently have a large-scale program to ensure UUIFB for the nearly 50% of births occurring at home. In the short term, national UUIFB coverage in all four settings can only substantially increase if UUIFB at home births is addressed. Evidence suggests that community-based programs for PPH prevention at home births using misoprostol achieve the greatest coverage through advance distribution by community health agents at home visits and self-administration [22].

Because of the nature of the exercise, estimates are dependent on the quality of data available. Issues with data quality and gaps became evident through the exercise in all four settings. An important activity of the exercise was advocacy for improved data collection and quality related to UUIFB, similar to experiences from data-use workshops [31]. Dissemination of the data may stimulate greater attention to measurement of this key indicator and hence better future estimates. The rapidity of the exercise allows for quick input into program planning and makes possible repeated measurements. Since the panels developed a list of priority interventions to improve UUIFB coverage and its measurement, these repeat measures could be used to track progress.

Limitations

This exercise was designed to provide for the first time population-level estimates in a field with a notable lack of information. To do this, the panels made educated judgments about divergent estimates for some parameters and made rough estimates of others in order to arrive at its final national coverage figure. The data sources that were considered by the expert panels ranged from population-based surveys (for birth location), to observational studies of service delivery, data from HMIS, and self-reported provider practice. In a few cases where no systematic information existed, expert opinion was used. There is no gold standard methodology for comparison. Given that there are no estimates for comparison, the validity of the UUIFB estimates cannot be objectively assessed. The figures on UUIFB coverage for some birth locations were the least precise data element with the widest possible range. The uncertainty in the estimation of this parameter was highlighted in those instances in which more than one estimate was available, as these were sometimes divergent. None of the exercises had data from current, nationally representative studies on uterotonic use after birth, and thus had to extrapolate findings from studies not meant for this purpose. Expert panels also used their own judgment in assigning weight to data of varying levels of quality and scope, with facilitation guidance from experts on measurement issues. Some of the major extrapolation challenges the panels faced included measurements of the use of different types of uterotonic separately; measurements which quantified uterotonic use in a timeframe that did not correspond exactly to the concept of UUIFB (e.g., one minute after birth or three minutes after birth); and use of data from small and/or old studies. This methodology should be seen as an interim step toward full integration of indicators on uterotonic coverage, both for facility and home birth. There should be follow-up to encourage progress programmatically and in collecting more complete and accurate information.

Conclusions

The UUIFB coverage estimation exercise produced estimated levels of coverage in all four settings that were much lower than desired or anticipated by many panel members. While the validity of the estimates is untested because there is no gold standard for comparison, the exercise fills an important gap in monitoring of maternal health programs by measuring intervention coverage of all births. The exercise raised awareness among national experts of low levels of UUIFB and provided them with information for monitoring and planning that was previously unavailable. Participants felt the process was feasible, transparent and accurate enough to be actionable. It highlighted critical gaps in the measurement of uterotonic provision. It is recommended in settings where PPH is a significant cause of maternal mortality and PPH prevention interventions are being implemented. UUIFB coverage estimates can provide useful data to help plan efforts to accelerate national and global efforts to reduce maternal mortality. Similar estimation exercises could be devised for other key maternal health interventions for which information is also currently lacking – for instance, use of magnesium sulfate for cases of eclampsia and severe pre-eclampsia.

Abbreviations

AMTSL:

Active management of the third stage of labor

DHS:

Demographic and health survey

HMIS:

Health management information system

MCHIP:

Maternal and Child Health Integrated Program

MICS:

Multiple Indicator Cluster Survey

MOH:

Ministry of Health

NGO:

Non-governmental organization

PPH:

Postpartum hemorrhage

SBA:

Skilled birth attendant

UNFPA:

United Nations Population Fund

UUIFB:

Uterotonic use immediately following birth

USAID:

United States Agency for International Development

WHO:

World Health Organization

References

  1. 1.

    Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, et al. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):956.

  2. 2.

    Say L, Chou D, Gemmill A, Tunçalp O, Moller A, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014;2(6):E323–33.

  3. 3.

    World Health Organization. WHO Recommendations for the Prevention and Treatment of Postpartum Hemorrhage. Geneva: World Health Organization; 2012.

  4. 4.

    Requejo JH, Bryce J, Victora C, Deixel A. Accountability for Maternal, Newborn and Child Survival: The 2013 Update. Geneva: World Health Organization; 2013.

  5. 5.

    Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB, et al. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: A randomized controlled trial. Lancet. 2006;368:1248–53.

  6. 6.

    United Nations. UN Commission on Life-Saving Commodities for Women and Children: Commissioners’ Report, September 2012. New York: Un Commission on Life Saving Commodities; 2012.

  7. 7.

    MCHIP. National Programs for the Prevention and Management of Postpartum Hemorrhage and Pre-Eclampsia/Eclampsia: A Global Survey, 2012. Washington DC: Maternal and Child Health Integrated Program; 2013.

  8. 8.

    World Health Organization. Fulfilling the Health Agenda for Women and Children The 2014 Report. Countdown to 2015 Maternal, Newborn and Child Survival. 20 Avenue Appia, 1211 Geneva 27, Switzerland: WHO Press, World Health Organization; 2014.

  9. 9.

    Campbell SM, Braspenning J, Hutchinson A, Marshall M. Research methods used in developing and applying quality indicators in primary care. Qual Saf Health Care. 2002;11:358–64.

  10. 10.

    Pollard S, Mathai M, Walker N. Estimating the impact of interventions on cause-specific maternal mortality: a Delphi approach. BMC Public Health. 2013;13 Suppl 3:S12.

  11. 11.

    Blencowe H, Cousens S, Mullany L, Lee A, Kerber K, Wall S, et al. Clean birth and postnatal care practices to reduce neonatal deaths from sepsis and tetanus: a systematic review and Delphi estimation of mortality effect. BMC Public Health. 2011;11 Suppl 3:S11.

  12. 12.

    Vital Statistics Division, Office of the Registrar General & Census Commissioner, Government of India. Annual Health Survey 2010–11 Fact Sheet Jharkhand. New Delhi: Offivce of the Registrar and Census Commissionder, Ministry of Home Affairs, Government of India; 2012.

  13. 13.

    Ministry of Planning and International Cooperation, Republic of Yemen. National Social Protection Monitoring Survey of Yemen: Baseline Analytical Report June 2013. Brasilia: United Nationas Development Programme and the United Nationas Childrens’ Fund; 2014.

  14. 14.

    MCHIP and Mozambique Ministry of Health. Estimation of National Coverage of Uterotonic in the Third Stage of Labor: Report of the Meeting of the Expert Panel, Mozambique 23 April 2013. Washington DC: Maternal and Child Health Integrated Program; 2013.

  15. 15.

    MCHIP and Jharkhand State Ministry of Health. Estimation of National Coverage of Uterotonic in the Third Stage of Labour: Report of the Meeting of the Expert Panel, Jharkhand State, India, June 2013. Washington DC: Matenal and Child Health Integrated Program; 2013.

  16. 16.

    MCHIP. Quality and Humanization of Care Assessment (QHCA): A Study of the Quality of Maternal and Newborn Care Delivered in Mozambique’s Model Maternities. 2013. Washington DC: Maternal and Child Integrated Program; 2013.

  17. 17.

    MCHIP. Quality of Care for Prevention and Management of Common Maternal and Newborn Complications: A study of 12 regions in Tanzania. Report 2: Findings on Labour, Delivery and Newborn Care. Washington DC: Maternal nad Child Health Integrated Program; 2013.

  18. 18.

    Ministry of Health, Republic of Mozambique and UNFPA. Second Survey of Availability of Modern Contraceptives and Essential Lifesaving Maternal/Reproductive Health Medicines in Service Delivery Points. Report of Mozambique 2011. Maputo: UNFPA/Mozambique; 2012.

  19. 19.

    Begley CM, Gyte GML, Murphy DJ, Devane D, McDonald SJ, McGuire W. Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews. 2010; (7):CD007412. doi:10.1002/14651858.CD007412.pub2 2010

  20. 20.

    Gülmezoglu AM, Lumbiganon P, Landoulsi S, Widmer M, Abdel Aleem H, Festin M, et al. Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial. Lancet. 2012;379:1721–7.

  21. 21.

    Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews 2013. (Issue 7). doi:10.1002/14651858.CD006431.pub3

  22. 22.

    Smith JM, Gubin R, Holston M, Fullerton J, Prata N. Misoprostol for postpartum hemorrhage prevention at home birth: an integrative review of global implementation experience to date. BMC Pregnancy Childbirth. 2013;13:44.

  23. 23.

    Stanton C, Armbruster D, Knight R, Ariawan I, Gbangbade S, Getachew A, et al. Use of active management of the third stage of labour in seven developing countries. Bull World Health Organ. 2009;87(3):207–15.

  24. 24.

    Stanton CK, Rawlins B, Drake M, dos Anjos M, Cantor D, Chongo L, et al. Measuring coverage in MNCH: testing the validity of Women’s self-report of Key maternal and newborn health interventions during the peripartum period in Mozambique. PLoS One. 2012;8(5):e60694.

  25. 25.

    The Policy Project. Maternal and Neonatal Program Effort Index. [http://www.policyproject.com/pubs/mnpi/getmnpi.cfm]

  26. 26.

    Hogerzeil H, Walker G, De Goeg MJ. Stability of oxytocic injectables in tropical climates: results of field surveys and simulation studies on ergometrine, methylergometrine, and oxytocin. In: WHO Action programme on Essential Drugs, Safe Motherhood Research Programme. EDM Research Series No. 008. Geneva: World Health Organization; 1993.

  27. 27.

    Ghana Food and Drugs Authority and the Promoting the Quality of Medicines Program. Post-Market Quality Surveillance Project Maternal Healthcare Products (Oxytocin and Ergometrine) on the Ghanaian Market Report of First Round. Rockville: United States Pharmacopoea and Ghana Food and Drugs Authority Laboratory Services Department; 2013.

  28. 28.

    Pribluda V. Quality of Oxytocin Injections: A Case Study in Indonesia. [http://www.youtube.com/watch?v=8DHuCLWT3C0&list=PL-aX6IpY69SxCDROFXh_rufEvMOOOJpgU]

  29. 29.

    Stanton C, Koski A, Cofie P, Mirzabagi E, Grady BL, Brooke S. Uterotonic drug quality: an assessment of the potency of injectable uterotonic drugs purchased by simulated clients in three districts in Ghana. BMJ Open. 2012;2:e000431.

  30. 30.

    PATH: Working Paper: Medicines for Maternal Health Working paper: Prepared for the United Nations Commission on Life-Saving Commodities for Women and Children. 2012 http://www.everywomaneverychild.org/images/Key_Data_and_Findings_Maternal_Health_Medicines_FINAL_3_26_2012__COMPLETE_reduced.pdf. Accessed October 2014.

  31. 31.

    Braa J, Heywood A, Sahaya S. Improving quality and use of data through data-use workshops: Zanzibar, United Republic of Tanzania. Bull World Health Organ. 2012;90:379–84.

Download references

Acknowledgements

The authors would like to thank USAID for their technical support and funding of the exercise and manuscript, especially Deborah Armbruster and Nahed Matta. The authors would like to thank the participants of the global expert group (listed in alphabetical order, with organizational affiliation for identification purposes only): Deborah Armbruster (USAID); Patsy Bailey (FHI360/AMDD); Linda Bartlett (Johns Hopkins Bloomberg School of Public Health); Ann Blanc (Population Council); Neal Brandes (USAID); Kate Brickson (Maternal and Child Survival Program); Oona Campbell (London School of Hygiene and Tropical Medicine); Sheena Currie (Maternal and Child Survival Program); Mary Drake (Maternal and Child Survival Program); Karen Fogg (USAID); UnJa Hayes (USAID); Steve Hodgins (Save the Children); Mandy Hovland (Maternal and Child Survival Program); Denise Jamieson (Centers for Disease Control and Prevention); Ronald Magarick (Jhpiego); Nahed Matta (USAID); Susan Moffson (Maternal and Child Survival Program); Allisyn Moran (USAID); Khatidja Naithani (Maternal and Child Survival Program); Kola Oyediran (MEASURE Evaluation); Barbara Rawlins (Maternal and Child Survival Program); Heather Rosen (Johns Hopkins University); Harshad Sanghvi (Jhpiego); Rima Shretta (MSH); Cindy Stanton (Johns Hopkins Bloomberg School of Public Health); Deepti Tanuku (Jhpiego); Vandana Tripathi (Johns Hopkins Bloomberg School of Public Health); and Beth Yeager (MSH). The authors would also like to thank all the participants in the expert panels in Mozambique, Tanzania, Jharkhand, and Yemen, as well as MCHIP country office staff who provided assistance to the process.

Author information

Correspondence to Jim Ricca.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JR, JMS, JV and VD conceptualized the exercise and developed the algorithm with input from MP. JR, JMS, GS, SP, NA, MP and DB conducted expert panel surveys, facilitated the exercises in-country, including facilitating the analysis of the coverage estimates. JR, JMS, VD, SS and JV drafted the manuscript. All authors read and approved the final manuscript.

Authors’ information

JR, JMS, JV, VD, GS, SP, SS and DB work on MCHIP and have worked extensively on maternal health programming. MP leads monitoring and evaluation efforts at Jhpiego Tanzania.

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Uterotonic
  • Estimation
  • Postpartum hemorrhage (PPH)
  • Delphi method
  • UUIFB